Immunization with SARS coronavirus vaccines leads to pulmonary immunopathology on challenge with the SARS virus.
Identifieur interne : 001339 ( PubMed/Checkpoint ); précédent : 001338; suivant : 001340Immunization with SARS coronavirus vaccines leads to pulmonary immunopathology on challenge with the SARS virus.
Auteurs : Chien-Te Tseng [États-Unis] ; Elena Sbrana ; Naoko Iwata-Yoshikawa ; Patrick C. Newman ; Tania Garron ; Robert L. Atmar ; Clarence J. Peters ; Robert B. CouchSource :
- PloS one [ 1932-6203 ] ; 2012.
Descripteurs français
- KwdFr :
- Animaux, Cellules Vero, Femelle, Granulocytes éosinophiles (immunologie), Lymphocytes auxiliaires Th2 (immunologie), Poumon (anatomopathologie), Poumon (virologie), Protéines de l'enveloppe virale (immunologie), Souris, Souris de lignée BALB C, Souris de lignée C57BL, Syndrome respiratoire aigu sévère (), Syndrome respiratoire aigu sévère (virologie), Techniques de culture de tissus, Vaccination (effets indésirables), Vaccins antiviraux (effets indésirables), Vaccins antiviraux (immunologie), Vaccins inactivés (effets indésirables), Vaccins inactivés (immunologie), Virus du SRAS (immunologie).
- MESH :
- anatomopathologie : Poumon.
- effets indésirables : Vaccination, Vaccins antiviraux, Vaccins inactivés.
- immunologie : Granulocytes éosinophiles, Lymphocytes auxiliaires Th2, Protéines de l'enveloppe virale, Vaccins antiviraux, Vaccins inactivés, Virus du SRAS.
- virologie : Poumon, Syndrome respiratoire aigu sévère.
- Animaux, Cellules Vero, Femelle, Souris, Souris de lignée BALB C, Souris de lignée C57BL, Syndrome respiratoire aigu sévère, Techniques de culture de tissus.
English descriptors
- KwdEn :
- Animals, Chlorocebus aethiops, Eosinophils (immunology), Female, Lung (pathology), Lung (virology), Mice, Mice, Inbred BALB C, Mice, Inbred C57BL, SARS Virus (immunology), Severe Acute Respiratory Syndrome (prevention & control), Severe Acute Respiratory Syndrome (virology), Th2 Cells (immunology), Tissue Culture Techniques, Vaccination (adverse effects), Vaccines, Inactivated (adverse effects), Vaccines, Inactivated (immunology), Vero Cells, Viral Envelope Proteins (immunology), Viral Vaccines (adverse effects), Viral Vaccines (immunology).
- MESH :
- chemical , adverse effects : Vaccines, Inactivated, Viral Vaccines.
- adverse effects : Vaccination.
- immunology : Eosinophils, SARS Virus, Th2 Cells, Vaccines, Inactivated, Viral Envelope Proteins, Viral Vaccines.
- pathology : Lung.
- prevention & control : Severe Acute Respiratory Syndrome.
- virology : Lung, Severe Acute Respiratory Syndrome.
- Animals, Chlorocebus aethiops, Female, Mice, Mice, Inbred BALB C, Mice, Inbred C57BL, Tissue Culture Techniques, Vero Cells.
Abstract
Severe acute respiratory syndrome (SARS) emerged in China in 2002 and spread to other countries before brought under control. Because of a concern for reemergence or a deliberate release of the SARS coronavirus, vaccine development was initiated. Evaluations of an inactivated whole virus vaccine in ferrets and nonhuman primates and a virus-like-particle vaccine in mice induced protection against infection but challenged animals exhibited an immunopathologic-type lung disease.
DOI: 10.1371/journal.pone.0035421
PubMed: 22536382
Affiliations:
Links toward previous steps (curation, corpus...)
Links to Exploration step
pubmed:22536382Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Immunization with SARS coronavirus vaccines leads to pulmonary immunopathology on challenge with the SARS virus.</title><author><name sortKey="Tseng, Chien Te" sort="Tseng, Chien Te" uniqKey="Tseng C" first="Chien-Te" last="Tseng">Chien-Te Tseng</name><affiliation wicri:level="2"><nlm:affiliation>Department of Microbiology and Immunology, The University of Texas Medical Branch, Galveston, Texas, United States of America.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Microbiology and Immunology, The University of Texas Medical Branch, Galveston, Texas</wicri:regionArea><placeName><region type="state">Texas</region></placeName></affiliation></author><author><name sortKey="Sbrana, Elena" sort="Sbrana, Elena" uniqKey="Sbrana E" first="Elena" last="Sbrana">Elena Sbrana</name></author><author><name sortKey="Iwata Yoshikawa, Naoko" sort="Iwata Yoshikawa, Naoko" uniqKey="Iwata Yoshikawa N" first="Naoko" last="Iwata-Yoshikawa">Naoko Iwata-Yoshikawa</name></author><author><name sortKey="Newman, Patrick C" sort="Newman, Patrick C" uniqKey="Newman P" first="Patrick C" last="Newman">Patrick C. Newman</name></author><author><name sortKey="Garron, Tania" sort="Garron, Tania" uniqKey="Garron T" first="Tania" last="Garron">Tania Garron</name></author><author><name sortKey="Atmar, Robert L" sort="Atmar, Robert L" uniqKey="Atmar R" first="Robert L" last="Atmar">Robert L. Atmar</name></author><author><name sortKey="Peters, Clarence J" sort="Peters, Clarence J" uniqKey="Peters C" first="Clarence J" last="Peters">Clarence J. Peters</name></author><author><name sortKey="Couch, Robert B" sort="Couch, Robert B" uniqKey="Couch R" first="Robert B" last="Couch">Robert B. Couch</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2012">2012</date><idno type="RBID">pubmed:22536382</idno><idno type="pmid">22536382</idno><idno type="doi">10.1371/journal.pone.0035421</idno><idno type="wicri:Area/PubMed/Corpus">001372</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">001372</idno><idno type="wicri:Area/PubMed/Curation">001372</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">001372</idno><idno type="wicri:Area/PubMed/Checkpoint">001339</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">001339</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Immunization with SARS coronavirus vaccines leads to pulmonary immunopathology on challenge with the SARS virus.</title><author><name sortKey="Tseng, Chien Te" sort="Tseng, Chien Te" uniqKey="Tseng C" first="Chien-Te" last="Tseng">Chien-Te Tseng</name><affiliation wicri:level="2"><nlm:affiliation>Department of Microbiology and Immunology, The University of Texas Medical Branch, Galveston, Texas, United States of America.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Microbiology and Immunology, The University of Texas Medical Branch, Galveston, Texas</wicri:regionArea><placeName><region type="state">Texas</region></placeName></affiliation></author><author><name sortKey="Sbrana, Elena" sort="Sbrana, Elena" uniqKey="Sbrana E" first="Elena" last="Sbrana">Elena Sbrana</name></author><author><name sortKey="Iwata Yoshikawa, Naoko" sort="Iwata Yoshikawa, Naoko" uniqKey="Iwata Yoshikawa N" first="Naoko" last="Iwata-Yoshikawa">Naoko Iwata-Yoshikawa</name></author><author><name sortKey="Newman, Patrick C" sort="Newman, Patrick C" uniqKey="Newman P" first="Patrick C" last="Newman">Patrick C. Newman</name></author><author><name sortKey="Garron, Tania" sort="Garron, Tania" uniqKey="Garron T" first="Tania" last="Garron">Tania Garron</name></author><author><name sortKey="Atmar, Robert L" sort="Atmar, Robert L" uniqKey="Atmar R" first="Robert L" last="Atmar">Robert L. Atmar</name></author><author><name sortKey="Peters, Clarence J" sort="Peters, Clarence J" uniqKey="Peters C" first="Clarence J" last="Peters">Clarence J. Peters</name></author><author><name sortKey="Couch, Robert B" sort="Couch, Robert B" uniqKey="Couch R" first="Robert B" last="Couch">Robert B. Couch</name></author></analytic><series><title level="j">PloS one</title><idno type="eISSN">1932-6203</idno><imprint><date when="2012" type="published">2012</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Animals</term><term>Chlorocebus aethiops</term><term>Eosinophils (immunology)</term><term>Female</term><term>Lung (pathology)</term><term>Lung (virology)</term><term>Mice</term><term>Mice, Inbred BALB C</term><term>Mice, Inbred C57BL</term><term>SARS Virus (immunology)</term><term>Severe Acute Respiratory Syndrome (prevention & control)</term><term>Severe Acute Respiratory Syndrome (virology)</term><term>Th2 Cells (immunology)</term><term>Tissue Culture Techniques</term><term>Vaccination (adverse effects)</term><term>Vaccines, Inactivated (adverse effects)</term><term>Vaccines, Inactivated (immunology)</term><term>Vero Cells</term><term>Viral Envelope Proteins (immunology)</term><term>Viral Vaccines (adverse effects)</term><term>Viral Vaccines (immunology)</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Animaux</term><term>Cellules Vero</term><term>Femelle</term><term>Granulocytes éosinophiles (immunologie)</term><term>Lymphocytes auxiliaires Th2 (immunologie)</term><term>Poumon (anatomopathologie)</term><term>Poumon (virologie)</term><term>Protéines de l'enveloppe virale (immunologie)</term><term>Souris</term><term>Souris de lignée BALB C</term><term>Souris de lignée C57BL</term><term>Syndrome respiratoire aigu sévère ()</term><term>Syndrome respiratoire aigu sévère (virologie)</term><term>Techniques de culture de tissus</term><term>Vaccination (effets indésirables)</term><term>Vaccins antiviraux (effets indésirables)</term><term>Vaccins antiviraux (immunologie)</term><term>Vaccins inactivés (effets indésirables)</term><term>Vaccins inactivés (immunologie)</term><term>Virus du SRAS (immunologie)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Vaccines, Inactivated</term><term>Viral Vaccines</term></keywords><keywords scheme="MESH" qualifier="adverse effects" xml:lang="en"><term>Vaccination</term></keywords><keywords scheme="MESH" qualifier="anatomopathologie" xml:lang="fr"><term>Poumon</term></keywords><keywords scheme="MESH" qualifier="effets indésirables" xml:lang="fr"><term>Vaccination</term><term>Vaccins antiviraux</term><term>Vaccins inactivés</term></keywords><keywords scheme="MESH" qualifier="immunologie" xml:lang="fr"><term>Granulocytes éosinophiles</term><term>Lymphocytes auxiliaires Th2</term><term>Protéines de l'enveloppe virale</term><term>Vaccins antiviraux</term><term>Vaccins inactivés</term><term>Virus du SRAS</term></keywords><keywords scheme="MESH" qualifier="immunology" xml:lang="en"><term>Eosinophils</term><term>SARS Virus</term><term>Th2 Cells</term><term>Vaccines, Inactivated</term><term>Viral Envelope Proteins</term><term>Viral Vaccines</term></keywords><keywords scheme="MESH" qualifier="pathology" xml:lang="en"><term>Lung</term></keywords><keywords scheme="MESH" qualifier="prevention & control" xml:lang="en"><term>Severe Acute Respiratory Syndrome</term></keywords><keywords scheme="MESH" qualifier="virologie" xml:lang="fr"><term>Poumon</term><term>Syndrome respiratoire aigu sévère</term></keywords><keywords scheme="MESH" qualifier="virology" xml:lang="en"><term>Lung</term><term>Severe Acute Respiratory Syndrome</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Animals</term><term>Chlorocebus aethiops</term><term>Female</term><term>Mice</term><term>Mice, Inbred BALB C</term><term>Mice, Inbred C57BL</term><term>Tissue Culture Techniques</term><term>Vero Cells</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Animaux</term><term>Cellules Vero</term><term>Femelle</term><term>Souris</term><term>Souris de lignée BALB C</term><term>Souris de lignée C57BL</term><term>Syndrome respiratoire aigu sévère</term><term>Techniques de culture de tissus</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Severe acute respiratory syndrome (SARS) emerged in China in 2002 and spread to other countries before brought under control. Because of a concern for reemergence or a deliberate release of the SARS coronavirus, vaccine development was initiated. Evaluations of an inactivated whole virus vaccine in ferrets and nonhuman primates and a virus-like-particle vaccine in mice induced protection against infection but challenged animals exhibited an immunopathologic-type lung disease.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">22536382</PMID><DateCompleted><Year>2012</Year><Month>08</Month><Day>31</Day></DateCompleted><DateRevised><Year>2019</Year><Month>12</Month><Day>10</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1932-6203</ISSN><JournalIssue CitedMedium="Internet"><Volume>7</Volume><Issue>4</Issue><PubDate><Year>2012</Year></PubDate></JournalIssue><Title>PloS one</Title><ISOAbbreviation>PLoS ONE</ISOAbbreviation></Journal><ArticleTitle>Immunization with SARS coronavirus vaccines leads to pulmonary immunopathology on challenge with the SARS virus.</ArticleTitle><Pagination><MedlinePgn>e35421</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1371/journal.pone.0035421</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Severe acute respiratory syndrome (SARS) emerged in China in 2002 and spread to other countries before brought under control. Because of a concern for reemergence or a deliberate release of the SARS coronavirus, vaccine development was initiated. Evaluations of an inactivated whole virus vaccine in ferrets and nonhuman primates and a virus-like-particle vaccine in mice induced protection against infection but challenged animals exhibited an immunopathologic-type lung disease.</AbstractText><AbstractText Label="DESIGN" NlmCategory="METHODS">Four candidate vaccines for humans with or without alum adjuvant were evaluated in a mouse model of SARS, a VLP vaccine, the vaccine given to ferrets and NHP, another whole virus vaccine and an rDNA-produced S protein. Balb/c or C57BL/6 mice were vaccinated i.m. on day 0 and 28 and sacrificed for serum antibody measurements or challenged with live virus on day 56. On day 58, challenged mice were sacrificed and lungs obtained for virus and histopathology.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">All vaccines induced serum neutralizing antibody with increasing dosages and/or alum significantly increasing responses. Significant reductions of SARS-CoV two days after challenge was seen for all vaccines and prior live SARS-CoV. All mice exhibited histopathologic changes in lungs two days after challenge including all animals vaccinated (Balb/C and C57BL/6) or given live virus, influenza vaccine, or PBS suggesting infection occurred in all. Histopathology seen in animals given one of the SARS-CoV vaccines was uniformly a Th2-type immunopathology with prominent eosinophil infiltration, confirmed with special eosinophil stains. The pathologic changes seen in all control groups lacked the eosinophil prominence.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">These SARS-CoV vaccines all induced antibody and protection against infection with SARS-CoV. However, challenge of mice given any of the vaccines led to occurrence of Th2-type immunopathology suggesting hypersensitivity to SARS-CoV components was induced. Caution in proceeding to application of a SARS-CoV vaccine in humans is indicated.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Tseng</LastName><ForeName>Chien-Te</ForeName><Initials>CT</Initials><AffiliationInfo><Affiliation>Department of Microbiology and Immunology, The University of Texas Medical Branch, Galveston, Texas, United States of America.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sbrana</LastName><ForeName>Elena</ForeName><Initials>E</Initials></Author><Author ValidYN="Y"><LastName>Iwata-Yoshikawa</LastName><ForeName>Naoko</ForeName><Initials>N</Initials></Author><Author ValidYN="Y"><LastName>Newman</LastName><ForeName>Patrick C</ForeName><Initials>PC</Initials></Author><Author ValidYN="Y"><LastName>Garron</LastName><ForeName>Tania</ForeName><Initials>T</Initials></Author><Author ValidYN="Y"><LastName>Atmar</LastName><ForeName>Robert L</ForeName><Initials>RL</Initials></Author><Author ValidYN="Y"><LastName>Peters</LastName><ForeName>Clarence J</ForeName><Initials>CJ</Initials></Author><Author ValidYN="Y"><LastName>Couch</LastName><ForeName>Robert B</ForeName><Initials>RB</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>N01AI30039</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>N01 AI 30039</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2012</Year><Month>04</Month><Day>20</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>PLoS One</MedlineTA><NlmUniqueID>101285081</NlmUniqueID><ISSNLinking>1932-6203</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015164">Vaccines, Inactivated</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014759">Viral Envelope Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014765">Viral Vaccines</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="ErratumIn"><RefSource>PLoS One. 2012;7(8). doi:10.1371/annotation/2965cfae-b77d-4014-8b7b-236e01a35492</RefSource></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002522" MajorTopicYN="N">Chlorocebus aethiops</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004804" MajorTopicYN="N">Eosinophils</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008168" MajorTopicYN="N">Lung</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008807" MajorTopicYN="N">Mice, Inbred BALB C</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008810" MajorTopicYN="N">Mice, Inbred C57BL</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D045473" MajorTopicYN="N">SARS Virus</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D045169" MajorTopicYN="N">Severe Acute Respiratory Syndrome</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="Y">prevention & control</QualifierName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018418" MajorTopicYN="N">Th2 Cells</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D046509" MajorTopicYN="N">Tissue Culture Techniques</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014611" MajorTopicYN="N">Vaccination</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015164" MajorTopicYN="N">Vaccines, Inactivated</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014709" MajorTopicYN="N">Vero Cells</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014759" MajorTopicYN="N">Viral Envelope Proteins</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014765" MajorTopicYN="N">Viral Vaccines</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2012</Year><Month>01</Month><Day>31</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2012</Year><Month>03</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2012</Year><Month>4</Month><Day>27</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2012</Year><Month>4</Month><Day>27</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2012</Year><Month>9</Month><Day>1</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">22536382</ArticleId><ArticleId IdType="doi">10.1371/journal.pone.0035421</ArticleId><ArticleId IdType="pii">PONE-D-12-03114</ArticleId><ArticleId IdType="pmc">PMC3335060</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Am J Epidemiol. 1969 Apr;89(4):422-34</Citation><ArticleIdList><ArticleId IdType="pubmed">4305198</ArticleId></ArticleIdList></Reference><Reference><Citation>J Virol. 2001 Dec;75(24):12421-30</Citation><ArticleIdList><ArticleId IdType="pubmed">11711632</ArticleId></ArticleIdList></Reference><Reference><Citation>J Exp Med. 1995 Feb 1;181(2):713-21</Citation><ArticleIdList><ArticleId IdType="pubmed">7836924</ArticleId></ArticleIdList></Reference><Reference><Citation>J Virol. 1996 May;70(5):2852-60</Citation><ArticleIdList><ArticleId IdType="pubmed">8627759</ArticleId></ArticleIdList></Reference><Reference><Citation>Proc Natl Acad Sci U S A. 1996 Oct 29;93(22):12467-72</Citation><ArticleIdList><ArticleId IdType="pubmed">8901605</ArticleId></ArticleIdList></Reference><Reference><Citation>Immunity. 1997 May;6(5):541-9</Citation><ArticleIdList><ArticleId IdType="pubmed">9175832</ArticleId></ArticleIdList></Reference><Reference><Citation>Science. 2005 Oct 28;310(5748):676-9</Citation><ArticleIdList><ArticleId IdType="pubmed">16195424</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Rev Immunol. 2005 Dec;5(12):917-27</Citation><ArticleIdList><ArticleId IdType="pubmed">16322745</ArticleId></ArticleIdList></Reference><Reference><Citation>Vaccine. 2006 Jan 30;24(5):652-61</Citation><ArticleIdList><ArticleId IdType="pubmed">16214268</ArticleId></ArticleIdList></Reference><Reference><Citation>J Gen Virol. 2006 Mar;87(Pt 3):641-50</Citation><ArticleIdList><ArticleId IdType="pubmed">16476986</ArticleId></ArticleIdList></Reference><Reference><Citation>Vaccine. 2006 Apr 24;24(17):3624-31</Citation><ArticleIdList><ArticleId IdType="pubmed">16497416</ArticleId></ArticleIdList></Reference><Reference><Citation>PLoS Med. 2006 Dec;3(12):e525</Citation><ArticleIdList><ArticleId IdType="pubmed">17194199</ArticleId></ArticleIdList></Reference><Reference><Citation>J Virol. 2007 Feb;81(3):1162-73</Citation><ArticleIdList><ArticleId IdType="pubmed">17108019</ArticleId></ArticleIdList></Reference><Reference><Citation>Immunol Res. 2007;39(1-3):225-39</Citation><ArticleIdList><ArticleId IdType="pubmed">17917067</ArticleId></ArticleIdList></Reference><Reference><Citation>Expert Rev Vaccines. 2007 Oct;6(5):723-39</Citation><ArticleIdList><ArticleId IdType="pubmed">17931153</ArticleId></ArticleIdList></Reference><Reference><Citation>Antivir Ther. 2007;12(7):1107-13</Citation><ArticleIdList><ArticleId IdType="pubmed">18018769</ArticleId></ArticleIdList></Reference><Reference><Citation>Vaccine. 2008 Feb 6;26(6):797-808</Citation><ArticleIdList><ArticleId IdType="pubmed">18191004</ArticleId></ArticleIdList></Reference><Reference><Citation>J Virol. 2008 Mar;82(5):2040-55</Citation><ArticleIdList><ArticleId IdType="pubmed">17928346</ArticleId></ArticleIdList></Reference><Reference><Citation>Virus Res. 2008 Apr;133(1):45-62</Citation><ArticleIdList><ArticleId IdType="pubmed">17416434</ArticleId></ArticleIdList></Reference><Reference><Citation>J Virol. 2008 Aug;82(15):7721-4</Citation><ArticleIdList><ArticleId IdType="pubmed">18463152</ArticleId></ArticleIdList></Reference><Reference><Citation>J Gen Virol. 2008 Sep;89(Pt 9):2136-46</Citation><ArticleIdList><ArticleId IdType="pubmed">18753223</ArticleId></ArticleIdList></Reference><Reference><Citation>J Immunol. 2008 Nov 1;181(9):6337-48</Citation><ArticleIdList><ArticleId IdType="pubmed">18941225</ArticleId></ArticleIdList></Reference><Reference><Citation>Vaccine. 2008 Nov 25;26(50):6338-43</Citation><ArticleIdList><ArticleId IdType="pubmed">18824060</ArticleId></ArticleIdList></Reference><Reference><Citation>J Virol. 2009 Jun;83(11):5451-65</Citation><ArticleIdList><ArticleId IdType="pubmed">19297479</ArticleId></ArticleIdList></Reference><Reference><Citation>Clin Gastroenterol Hepatol. 2009 Jul;7(7):749-755.e11</Citation><ArticleIdList><ArticleId IdType="pubmed">19345285</ArticleId></ArticleIdList></Reference><Reference><Citation>Viral Immunol. 2010 Apr;23(2):211-9</Citation><ArticleIdList><ArticleId IdType="pubmed">20374001</ArticleId></ArticleIdList></Reference><Reference><Citation>Immunology. 2010 Jun;130(2):254-61</Citation><ArticleIdList><ArticleId IdType="pubmed">20406307</ArticleId></ArticleIdList></Reference><Reference><Citation>Viral Immunol. 2010 Oct;23(5):509-19</Citation><ArticleIdList><ArticleId IdType="pubmed">20883165</ArticleId></ArticleIdList></Reference><Reference><Citation>Vaccine. 2011 Sep 2;29(38):6606-13</Citation><ArticleIdList><ArticleId IdType="pubmed">21762752</ArticleId></ArticleIdList></Reference><Reference><Citation>J Virol. 2011 Dec;85(23):12201-15</Citation><ArticleIdList><ArticleId IdType="pubmed">21937658</ArticleId></ArticleIdList></Reference><Reference><Citation>Comp Immunol Microbiol Infect Dis. 1981;4(2):175-89</Citation><ArticleIdList><ArticleId IdType="pubmed">6754243</ArticleId></ArticleIdList></Reference><Reference><Citation>JAMA. 2003 Jul 16;290(3):367-73</Citation><ArticleIdList><ArticleId IdType="pubmed">12865378</ArticleId></ArticleIdList></Reference><Reference><Citation>J Exp Med. 2002 Sep 16;196(6):859-65</Citation><ArticleIdList><ArticleId IdType="pubmed">12235218</ArticleId></ArticleIdList></Reference><Reference><Citation>N Engl J Med. 2003 Dec 18;349(25):2431-41</Citation><ArticleIdList><ArticleId IdType="pubmed">14681510</ArticleId></ArticleIdList></Reference><Reference><Citation>J Virol. 2004 Apr;78(7):3572-7</Citation><ArticleIdList><ArticleId IdType="pubmed">15016880</ArticleId></ArticleIdList></Reference><Reference><Citation>Science. 2004 Jun 18;304(5678):1808-10</Citation><ArticleIdList><ArticleId IdType="pubmed">15205534</ArticleId></ArticleIdList></Reference><Reference><Citation>Emerg Infect Dis. 2004 Jul;10(7):1293-6</Citation><ArticleIdList><ArticleId IdType="pubmed">15324552</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Epidemiol. 1969 Apr;89(4):405-21</Citation><ArticleIdList><ArticleId IdType="pubmed">4305197</ArticleId></ArticleIdList></Reference><Reference><Citation>N Engl J Med. 2003 May 15;348(20):1977-85</Citation><ArticleIdList><ArticleId IdType="pubmed">12671062</ArticleId></ArticleIdList></Reference><Reference><Citation>N Engl J Med. 2003 May 15;348(20):1986-94</Citation><ArticleIdList><ArticleId IdType="pubmed">12682352</ArticleId></ArticleIdList></Reference><Reference><Citation>N Engl J Med. 2003 May 15;348(20):1967-76</Citation><ArticleIdList><ArticleId IdType="pubmed">12690091</ArticleId></ArticleIdList></Reference><Reference><Citation>N Engl J Med. 2003 May 15;348(20):1953-66</Citation><ArticleIdList><ArticleId IdType="pubmed">12690092</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></pubmed><affiliations><list><country><li>États-Unis</li></country><region><li>Texas</li></region></list><tree><noCountry><name sortKey="Atmar, Robert L" sort="Atmar, Robert L" uniqKey="Atmar R" first="Robert L" last="Atmar">Robert L. Atmar</name><name sortKey="Couch, Robert B" sort="Couch, Robert B" uniqKey="Couch R" first="Robert B" last="Couch">Robert B. Couch</name><name sortKey="Garron, Tania" sort="Garron, Tania" uniqKey="Garron T" first="Tania" last="Garron">Tania Garron</name><name sortKey="Iwata Yoshikawa, Naoko" sort="Iwata Yoshikawa, Naoko" uniqKey="Iwata Yoshikawa N" first="Naoko" last="Iwata-Yoshikawa">Naoko Iwata-Yoshikawa</name><name sortKey="Newman, Patrick C" sort="Newman, Patrick C" uniqKey="Newman P" first="Patrick C" last="Newman">Patrick C. Newman</name><name sortKey="Peters, Clarence J" sort="Peters, Clarence J" uniqKey="Peters C" first="Clarence J" last="Peters">Clarence J. Peters</name><name sortKey="Sbrana, Elena" sort="Sbrana, Elena" uniqKey="Sbrana E" first="Elena" last="Sbrana">Elena Sbrana</name></noCountry><country name="États-Unis"><region name="Texas"><name sortKey="Tseng, Chien Te" sort="Tseng, Chien Te" uniqKey="Tseng C" first="Chien-Te" last="Tseng">Chien-Te Tseng</name></region></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/SrasV1/Data/PubMed/Checkpoint
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001339 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd -nk 001339 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= SrasV1
|flux= PubMed
|étape= Checkpoint
|type= RBID
|clé= pubmed:22536382
|texte= Immunization with SARS coronavirus vaccines leads to pulmonary immunopathology on challenge with the SARS virus.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/RBID.i -Sk "pubmed:22536382" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd \
| NlmPubMed2Wicri -a SrasV1
| This area was generated with Dilib version V0.6.33. |  |